Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Carcinoma, Transitional Cell × epacadostat × Clear all

Phase

Phase 1/2 2 Phase 3 1 Phase 2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3 Head and Neck Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Pancreatic Neoplasms 2 Ovarian Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Uveal Melanoma 1 Thymus Neoplasms 1 Thymoma 1 Stomach Neoplasms 1 Sarcoma 1 Neoplasm Metastasis 1 Nasopharyngeal Carcinoma 1 Myelodysplastic Syndromes 1 Melanoma 1 Leukemia, Myeloid, Acute 1 Glioma 1 Glioblastoma 1 Gastrointestinal Stromal Tumors 1 Extensive Stage Small Cell Lung Carcinoma 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Endometrial Neoplasms 1 Cytopenia 1 Carcinoma, Transitional Cell 1 Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 31 Gemcitabine 26 Nivolumab 19 atezolizumab 16 Cisplatin 15 avelumab 14 Carboplatin 12 Docetaxel 10 enfortumab vedotin 8 durvalumab 7 Paclitaxel 7 Magnetic Resonance Spectroscopy 7 Specimen Handling 6 Ipilimumab 6 toripalimab 5 pemigatinib 5 cabozantinib 5 vinflunine 4 sacituzumab govitecan 4 Taxes 4 Pemetrexed 4 tislelizumab 3 cabazitaxel 3 Standard of Care 3 Mitomycin 3 Injections 3 Everolimus 3 Albumin-Bound Paclitaxel 3 sapanisertib 2 olaparib 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04586244 2025-10-30

Optimus

Incyte Corporation

Phase 2 Terminated

30 enrolled 12 charts

Carcinoma, Transitional Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡